论文部分内容阅读
目的:观察血府逐瘀胶囊联合注射用纤溶酶联用治疗视网膜静脉阻塞临床疗效。方法:82例视网膜静脉阻塞患者,随机分为2组,各41例。观察组采用血府逐瘀胶囊联合注射用纤溶酶治疗;对照组仅单独采用注射用纤溶酶治疗。15天为1疗程,治疗时间不超过3疗程。结果:总有效率观察组78.1%,对照组48.8%,2组比较,差异有统计学意义(P<0.05)。2组治疗前视力比较,差异无统计学意义(P>0.05),治疗后2周、4周、6周分别与对照组同时段比较,差异均有统计学意义(P<0.05)。观察组视网膜出血吸收情况明显优于对照组,Ⅳ度吸收的患者数量显著高于对照组,差异有统计学意义(P<0.05)。不良反应率观察组7.3%,对照组24.4%,2组比较,差异有统计学意义(P<0.05)。结论:血府逐瘀胶囊联合注射用纤溶酶联用治疗视网膜静脉阻塞临床疗效显著,可改善患者视力情况,减少并发症。
Objective: To observe the clinical effect of Xuefuzhuyu capsule combined with plasmin injection in the treatment of retinal vein occlusion. Methods: 82 patients with retinal vein occlusion were randomly divided into two groups, 41 cases each. The observation group was treated with Xuefu Zhuyu capsule combined with plasmin; the control group was treated with plasmin alone. 15 days for a course of treatment, treatment time does not exceed 3 courses. Results: The total effective rate was 78.1% in the observation group and 48.8% in the control group. There was significant difference between the two groups (P <0.05). There was no significant difference in visual acuity between the two groups before treatment (P> 0.05). There was significant difference between the two groups in the same period after 2 weeks, 4 weeks and 6 weeks after treatment (P <0.05). The observation group retinal hemorrhage absorption was significantly better than the control group, the number of patients with grade Ⅳ absorption was significantly higher than the control group, the difference was statistically significant (P <0.05). Adverse reaction rate was 7.3% in the observation group and 24.4% in the control group. There was significant difference between the two groups (P <0.05). Conclusion: The clinical curative effect of Xuefu Zhuyu Capsule combined with fibrinolytic enzyme for the treatment of retinal vein occlusion is significant, which can improve visual acuity and reduce complications in patients.